Search

Displaying results 9941 - 9950 of 10000 in total
  1. Drug

    Aetiocholanolone

    go.drugbank.com/drugs/DB02854
    Experimental

    Etiocholanolone is a major metabolite of testosterone and androstenedione in many mammalian species including humans. It is excreted in the urine. [PubChem]

  2. Drug

    Foralumab

    go.drugbank.com/drugs/DB16170
    Investigational

    Foralumab is under investigation in clinical trial NCT03291249 (Assessment of the Safety of Foralumab, an Oral Anti-cd3 Antibody, in Patients With NASH and T2DM).

  3. Drug

    Gonyautoxin II

    go.drugbank.com/drugs/DB19186
    Investigational

    Gonyautoxin II is under investigation in clinical trial NCT04799041 (Gonyautoxin 2/3 in the Treatment of Acute Back Pain: A Clinical Proof-of-concept Study).

  4. Drug

    Lepunafusp alfa

    go.drugbank.com/drugs/DB19011
    Investigational

    Lepunafusp alfa is under investigation in clinical trial NCT04453085 (An Extension Study of JR-171-101 Study in Patients With MPS I).

  5. Drug

    JPC-3210

    go.drugbank.com/drugs/DB15609
    Experimental

    It is an erythrocytic schizonticide with potent in vitro antimalarial activity against multidrug-resistant _Plasmodium falciparum_ lines, low cytotoxicity, potent in vivo efficacy against murine malaria … JPC-3210 is a potent antimalarial agent.

  6. Drug

    Fominoben

    go.drugbank.com/drugs/DB08968
    ApprovedWithdrawn

    Fominoben is an antitussive agent.

  7. Drug

    Carlumab

    go.drugbank.com/drugs/DB12718
    ApprovedWithdrawn

    Carlumab has been used in trials studying the treatment of Cancer and Prostate Cancer.

  8. Drug

    Anfibatide

    go.drugbank.com/drugs/DB15094
    Investigational

    Anfibatide is under investigation in clinical trial NCT01585259 (Anfibatide Phase Ib-IIa Clinical Trial).

  9. Drug

    Rintodestrant

    go.drugbank.com/drugs/DB21472
    Investigational

    Rintodestrant is under investigation in clinical trial NCT03455270 (G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer). … Rintodestrant is a small molecule drug.

  10. Drug

    SynOV1.1

    go.drugbank.com/drugs/DB17539
    Investigational

    SynOV1.1 is under investigation in clinical trial NCT04612504 (Synov1.1 Intratumoral Injection Study). … SynOV1.1 is an investigational cancer immunotherapy developed by SyngenTech.